Drug Profile
Research programme: supportive care therapeutics - Acacia Pharma
Latest Information Update: 13 Jun 2022
Price :
$50
*
At a glance
- Originator Acacia Pharma
- Class
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
Most Recent Events
- 09 Jun 2022 Acacia Pharma has been acquired by Eagle Pharmaceuticals
- 30 May 2012 No development reported - Preclinical for Chemotherapy induced nausea and vomiting in United Kingdom (IV)
- 30 May 2012 No development reported - Preclinical for Postoperative nausea and vomiting in United Kingdom (IV)